This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Epizyme Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Anahtar bilgiler
-16.7%
Kazanç büyüme oranı
-2.4%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 24.4% |
Özkaynak getirisi | n/a |
Net Marj | -391.9% |
Son Kazanç Güncellemesi | 30 Jun 2022 |
Yakın geçmiş performans güncellemeleri
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Gelir ve Gider Dağılımı
Epizyme nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 22 | 53 | -208 | 113 | 123 |
31 Mar 22 | 38 | -236 | 125 | 123 |
31 Dec 21 | 37 | -251 | 134 | 123 |
30 Sep 21 | 34 | -267 | 137 | 102 |
30 Jun 21 | 33 | -257 | 136 | 102 |
31 Mar 21 | 22 | -251 | 133 | 102 |
31 Dec 20 | 16 | -232 | 125 | 102 |
30 Sep 20 | 12 | -222 | 114 | 0 |
30 Jun 20 | 14 | -202 | 100 | 0 |
31 Mar 20 | 17 | -192 | 83 | 0 |
31 Dec 19 | 24 | -173 | 68 | 126 |
30 Sep 19 | 29 | -140 | 57 | 0 |
30 Jun 19 | 23 | -141 | 51 | 0 |
31 Mar 19 | 30 | -122 | 47 | 0 |
31 Dec 18 | 22 | -124 | 44 | 0 |
30 Sep 18 | 12 | -137 | 40 | 0 |
30 Jun 18 | 12 | -137 | 38 | 0 |
31 Mar 18 | 10 | -136 | 38 | 0 |
31 Dec 17 | 10 | -134 | 37 | 0 |
30 Sep 17 | 10 | -133 | 36 | 0 |
30 Jun 17 | 17 | -120 | 35 | 0 |
31 Mar 17 | 8 | -120 | 31 | 0 |
31 Dec 16 | 8 | -110 | 28 | 0 |
30 Sep 16 | 8 | -97 | 27 | 0 |
30 Jun 16 | 2 | -96 | 26 | 0 |
31 Mar 16 | 2 | -94 | 25 | 0 |
31 Dec 15 | 3 | -132 | 24 | 0 |
30 Sep 15 | 12 | -125 | 23 | 0 |
Kaliteli Kazançlar: EPZM is currently unprofitable.
Büyüyen Kar Marjı: EPZM is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: EPZM is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Büyüme Hızlandırma: Unable to compare EPZM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: EPZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Özkaynak Getirisi
Yüksek ROE: EPZM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.